Positive results for palbociclib/cetuximab therapy in head and neck cancer

2016 ACS Heroes of Chemistry: Pfizer – IBRANCE® for the treatment of metastatic breast cancerПодробнее

EXTREME regimen vs. cetuximab + cisplatin + paclitaxel for recurrent/metastatic head and neck cancerПодробнее

Final results from PALLAS: adjuvant palbociclib in HR+/HER2- early breast cancerПодробнее

Study of Palbociclib after CDK & Endocrine Therapy in ER+/HER2- Metastatic Breast CancerПодробнее

Results of a Phase II Study of Palbociclib in Esophageal and Gastric CancerПодробнее

AMEERA-1 updates: amcenestrant plus palbociclib for patients with ER+/HER2– advanced breast cancerПодробнее

BCFNZ Webinar: Palbociclib (Ibrance) for advanced or metastatic HR+ breast cancer - NZ updateПодробнее

Palbociclib for platinum-resistant metastatic head and neck cancerПодробнее

Palbociclib (IBRANCE) Revs Up Metastatic Breast Cancer in PATINA Results - SABCS - Otto Metzger, MDПодробнее

PALOMA-3: Overall survival (OS) with palbociclib plus fulvestrant in HR+,HER2_ ABCПодробнее

Study Results for Nivolumab and Pembrolizumab in Head and Neck CancerПодробнее

PENELOPE-B: palbociclib with endocrine therapy in HR+, HER2-negative breast cancerПодробнее

Pembrolizumab for frontline head and neck cancer: KEYNOTE-048 resultsПодробнее

Cisplatin v cetuximab for HPV associated oropharyngeal cancerПодробнее

Palbociclib combinations on treatment of advanced breast cancer – Video abstract [ID 77033]Подробнее

Palbociclib in metastatic breast cancer. Discussion of the PALOMA-2 results.Подробнее

Palbociclib combo therapies for advanced breast cancerПодробнее

Dr. Lenz on Breakthrough Designation of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRCПодробнее

Afatinib Plus Cetuximab in Resistant Non-Small Cell Lung CancerПодробнее